A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Kunming Medical University1 site in 1 country200 target enrollmentJune 2008

ConditionsDepression Depression Secondary to Other Disease

InterventionsEscitalopram

DrugsEscitalopram

Overview

Phase: Not Applicable
Intervention: Escitalopram
Conditions: Depression
Sponsor: Kunming Medical University
Enrollment: 200
Locations: 1
Primary Endpoint: change of fMRI after medication
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is:

to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
to find possible predispose to MDD
to explore the DNA methylation status in depression;

Detailed Description

1. to explore the pathology of depression 2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease 3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Registry

clinicaltrials.gov

Start Date

June 2008

End Date

June 2011

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Kunming Medical University

Responsible Party

Principal Investigator

Yuqi Cheng

Vise director, psychiatry department, Kunming Medical University

Kunming Medical University

Eligibility Criteria

Inclusion Criteria

•DSM-IV Major Depression or Dysthymia
•Age 18-65
•Physically healthy
•Drug-free

Exclusion Criteria

•Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
•History of Psychosis or Epilepsy
•Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
•Bipolar I
•Need for wash-out from effective treatment in order to participate
•High suicide risk
•Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants